Axsome Therapeutics (AXSM) Return on Equity (2022 - 2025)
Historic Return on Equity for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 3.13%.
- Axsome Therapeutics' Return on Equity rose 500.0% to 3.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.13%, marking a year-over-year increase of 500.0%. This contributed to the annual value of 2.32% for FY2024, which is 7200.0% down from last year.
- Axsome Therapeutics' Return on Equity amounted to 3.13% in Q3 2025, which was up 500.0% from 3.91% recorded in Q2 2025.
- Axsome Therapeutics' 5-year Return on Equity high stood at 0.74% for Q3 2023, and its period low was 5.05% during Q1 2025.
- Moreover, its 4-year median value for Return on Equity was 2.13% (2024), whereas its average is 2.41%.
- In the last 5 years, Axsome Therapeutics' Return on Equity skyrocketed by 3600bps in 2023 and then crashed by -32800bps in 2025.
- Over the past 4 years, Axsome Therapeutics' Return on Equity (Quarter) stood at 1.4% in 2022, then rose by 26bps to 1.04% in 2023, then plummeted by -269bps to 3.83% in 2024, then increased by 18bps to 3.13% in 2025.
- Its last three reported values are 3.13% in Q3 2025, 3.91% for Q2 2025, and 5.05% during Q1 2025.